Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/10—Spiro-condensed systems

Definitions

• the invention relates to new pyridine derivatives of the formula I.
• R2 each unsubstituted or mono- or disubstituted by alkyl and / or alkoxy each with 1-4 C atoms, F, Cl, Br, OH and / or CF3 substituted phenyl or 2- or 3-thienyl radicals and R3 u.
• R4 each H, alkyl or alkoxy, each with 1-4 carbon atoms, F, Cl, Br, OH or CF3 mean, however, Y means CH if means, as well as their salts.
• the object of the invention was to find new compounds which can be used for the production of medicaments.
• the substances mentioned have valuable pharmacological properties with good tolerability. For example, they show effects, preferably steaming (eg sedating, tranquilizing, neuroleptic and / or antidepressant), which influence the central nervous system.
• the compounds have a dampening effect on the behavior in mice (methodology see Irwin, Psychopharmacologia 13 (1968), 222-257), inhibit the climbing behavior induced by apomorphine in mice (methodology see Costall et al., European J. Pharmacol. 50 (1968), 39-50) or induce contralateral rotational behavior in hemiparkinsonian rats (can be determined by the method of Ungerstedt et al., Brain Res.
• the invention relates to the pyridine derivatives of the formula I and their salts.
• the invention further relates to a process for the preparation of pyridine derivatives of the formula I and salts thereof, characterized in that a compound of the formula II Py-A-X1 II wherein A the group -C n H 2n -, X1 X or NH2, X is Cl, Br, J, OH or a reactive, functionally modified OH group and R1, Y, Z and n have the meanings given, with a compound of formula III X2-CH2CH2-G-CH2-X3 III wherein X2 u.
• the compounds of the formula I include the 2-R1-6-RA-pyridines (I ′), the 2-R1-4-RA-pyridines (I “), the 3-R1-5-RA-pyridines (I”' ) and the 2-RA-4-R1-pyridines (I “"). I "'and I”"are preferred.
• (4-R2-piperidinoalkyl) pyridines (Ia), namely 2-R1-6- (4-R2-piperidinoalkyl) pyridines (Iaa) 2-R1-4- (4-R2-piperidinoalkyl) pyridine (Iab) 3-R1-5- (4-R2-piperidinoalkyl) pyridine (Iac) 2- (4-R2-piperidinoalkyl) -4-R1-pyridine (Iad); (4-R2-1,2,3,6-tetrahydropyridylalkyl) pyridine (Ib), namely 2-R1-6- (4-R2-1,2,3,6-tetrahydropyridyl-alkyl) -pyridines (Iba) 2-R1-4- (4-R2-1,2,3,6-tetrahydropyridyl-alkyl) -pyridines (Ibb) 2- (4-R2-1,2,3,6-tetrahydropyridyl-alkyl
• Ia, Ib and Ic are preferred, in particular Iac, Iba, Ibb, Ibd, Icc, furthermore Iaa, Idc, Iec and Ifc.
• alkyl is preferably methyl, and also ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
• Alkoxy is preferably methoxy, furthermore also ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
• R1 and R2 are preferably unsubstituted phenyl. If R1 or R2 are substituted phenyl groups, these are preferably monosubstituted. However, they can also be substituted twice, where the substituents can be the same or different. Preferred substituents on the phenyl groups are methyl, ethyl, methoxy, ethoxy, F, Cl, Br and / or OH.
• R 1 and R 2 are preferably phenyl, furthermore o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-fluorophenyl, o-, m- or p-chlorophenyl, o-, m- or p-bromophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-trifluoromethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dimethylphenyl, 2,3-, 2,4-, 2,5-, 2,6- , 3,4- or 3,5-dimethylphenyl, 2,3-, 2,4-, 2,5-, 2,6- , 3,4-
• radicals R3 and R4 can be the same or different. They are preferably both H. Furthermore, one of these radicals is preferably H, the other F, Cl, OH or CF3.
• Some compounds of formula I can have one or more asymmetric carbon atoms. They can therefore be present as racemates, if several asymmetric carbon atoms are present, as mixtures of several racemates and in various optically active forms.
• the compounds of the formula I are otherwise prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc., New York), under reaction conditions as are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.
• the starting materials for the claimed process can also be formed in situ in such a way that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
• X1 is preferably X; accordingly in the compounds of formula III X2 and X3 are preferably together NH.
• the radical X is preferably Cl or Br; however, it can also mean J, OH or a reactive, functionally modified OH group, in particular alkylsulfonyloxy with 1-6 (for example methanesulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (for example benzenesulfonyloxy, p-toluenesulfonyloxy, 1- or 2-naphthalene -sulfonyloxy).
• the compounds of the formula I can be obtained in particular by reacting compounds of the formula Py-A-Cl or Py-A-Br with compounds of the formula III, in which X 2 and X 3 together represent an NH group (hereinafter referred to as IIIa).
• the iodine compounds of the formula Py-AJ are available, for example, by the action of potassium iodide on the associated p-toluenesulfonic acid ester.
• the amines of the formula Py-A-NH2 can be prepared, for example, from the halides with phthalimide potassium or by reducing the corresponding nitriles.
• Some of the compounds of the formula IIIa are known (cf. DE-OS 20 60 816) and e.g. obtainable by reacting 4-piperidone with organometallic compounds of the formula M-R2 (in which M is a Li atom or MgHal), subsequent hydrolysis to the corresponding 4-R2-4-hydroxypiperidines and, if desired, subsequent dehydration to 4-R2 -3,4-dehydro-piperidines and hydrogenation to 4-R2-piperidines.
• reaction of the compounds II and III proceeds according to methods known from the literature for the alkylation of amines.
• the components can be melted together without the presence of a solvent, if appropriate in a closed tube or in an autoclave. However, it is also possible to react the compounds in the presence of an inert solvent.
• suitable solvents are hydrocarbons, such as benzene, toluene, xylene; Ketones such as acetone, butanone; Alcohols such as methanol, ethanol, isopropanol, n-butanol; Ethers such as tetrahydrofuran (THF) or dioxane; Amides such as dimethylformamide (DMF) or N-methyl-pyrrolidone; Nitriles such as acetonitrile, optionally also mixtures of these solvents with one another or mixtures with water.
• hydrocarbons such as benzene, toluene, xylene
• Ketones such as acetone, butanone
• Alcohols such as methanol, ethanol, isopropanol, n-butanol
• Ethers such as tetrahydrofuran (THF) or dioxane
• Amides such as dimethylformamide (DMF) or N-methyl-pyrrolidone
• an acid-binding agent for example one Alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, sodium or calcium, or the addition of an organic base such as triethylamine, dimethylaniline, pyridine or quinoline or an excess of the amine component Py-A-NH2 or the compound of formula IIIa can be favorable.
• the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0 and 150 °, normally between 20 and 130 °.
• a compound of the formula I by containing a precursor which, instead of hydrogen atoms, contains one or more reducible groups and / or one or more additional CC and / or CN bonds , treated with a reducing agent, preferably at temperatures between -80 and + 250 ° in the presence of at least one inert solvent.
• Reducible (hydrogen replaceable) groups are especially oxygen in a carbonyl group, hydroxyl, arylsulfonyloxy (e.g. p-toluenesulfonyloxy), N-benzenesulfonyl, N-benzyl or O-benzyl.
• Preferred starting materials for the reduction correspond to the formula V. Py-LR V wherein L is a chain corresponding to the radical A, but one or more -CH2 group (s) are replaced by -CO group (s) and / or one or more hydrogen atoms are replaced by OH group (s).
• L is preferred - (CH2) n-1 -CO- [in particular -CO-, -CH2-CO- or -CH2CH2-CO-], furthermore, for example -CH (CH3) -CO-, -COCH2-, -COCO-, -COCH2CO-, -CO-CH2CH2-, CH2CO-CH2-, -CHOH-, -CH2-CHOH-, - (CH2) 2-CHOH-, -CHOH-CH2-, -CHOH -CO-.
• nascent hydrogen is used as the reducing agent, this can be generated, for example, by treating metals with weak acids or with bases.
• metals with weak acids or with bases.
• Suitable is also the use of sodium or another alkali metal in an alcohol such as ethanol, isopropanol, butanol, amyl or isoamyl alcohol or phenol.
• Sodium or aluminum amalgam in aqueous-alcoholic or aqueous solution are also suitable for generating the nascent hydrogen.
• the reaction can also be carried out in a heterogeneous phase, an aqueous and a benzene or toluene phase being expediently used.
• Complex metal hydrides such as LiAlH4, NaBH4, diisobutylaluminum hydride or NaAl (OCH2CH2OCH3) 2H2 and diborane can also be used particularly advantageously as reducing agents, if desired with the addition of catalysts such as BF3, AlCl3 or LiBr.
• Suitable solvents are in particular ethers such as diethyl ether, di-n-butyl ether, THF, dioxane, diglyme or 1,2-dimethoxyethane and hydrocarbons such as benzene.
• ethers such as diethyl ether, di-n-butyl ether, THF, dioxane, diglyme or 1,2-dimethoxyethane and hydrocarbons such as benzene.
• alcohols such as methanol or ethanol
• water and aqueous alcohols are suitable as solvents. These methods are preferably used at temperatures between -80 and + 150 °, in particular between about
• the reduction can also be varied by the Huang-Minlon method by reacting with hydrazine hydrate in a high-boiling, water-miscible solvent, such as diethylene glycol or triethylene glycol, in the presence of alkali, such as sodium hydroxide. The reaction mixture is usually boiled for about 3-4 hours. The water is then distilled off and the hydrazone formed is decomposed at temperatures up to about 200 °.
• the Wolff-Kishner reduction can also be carried out at room temperature in dimethyl sulfoxide with hydrazine.
• R is a 4-R2-1,2,3,6-tetrahydropyridyl group
• E it can be, for example, a splitting off of hydrogen halide, water (dehydration), a carboxylic acid or another acid, from ammonia or from HCN.
• Bases that can be used are: alkali metal hydroxides, alkali metal carbonates, alcoholates, such as, for example, potassium tert-butoxide, amines, such as, for example, dimethylaniline, Pyridine, collidine or quinoline; the solvents used are, for example, benzene, toluene, cyclohexane, THF or tert-butanol.
• the amines used as bases can also be used in excess as solvents.
• acids such as acetic acid, hydrochloric acid or mixtures of both are preferably used as the water-releasing agent.
• a solvent e.g. water or ethanol
• Elimination of acyl, alkylsulfonyl and alkoxysulfonyloxy or amino residues can be carried out under similar conditions.
• An elimination of sulfonic acid residues, such as those of the mesylates or tosylates, is carried out gently by boiling in DMF or dimethyl sulfoxide with alkali metal carbonates, for example Li2CO3, or with potassium acetate.
• Ammonia can already be split off by heating the salts of the corresponding amino compounds (especially the 4-amino derivatives).
• HE is generally eliminated from IV at temperatures between 0 and about 250 °, preferably between 50 and 200 °.
• a compound of the formula I can optionally be converted into another compound of the formula by methods known per se.
• ethers (O-alkyl derivatives) can be cleaved to give the corresponding hydroxy derivatives.
• the ethers can be split by treatment with dimethyl sulfide-boron tribromide complex, for example in toluene, 1,2-dichloroethane, THF or dimethyl sulfoxide, by fusing with pyridine or aniline hydrohalides, preferably pyridine hydrochloride, at about 150-250 °, with HBr / Acetic acid or with Al trihalides in chlorinated hydrocarbons such as 1,2-dichloroethane.
• a base of the formula I obtained can be converted into the associated acid addition salt using an acid.
• Acids which provide physiologically acceptable salts are preferably suitable for this reaction.
• So inorganic acids can be used, e.g. Sulfuric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acids, nitric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, such as formic acid, acetic acid, acetic acid, acetic acid Pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, benzoic acid, salicylic acid, 2-phenylpropionic acid, citric acid, gluconic acid, ascorbic acid,
• the free bases of the formula I can be liberated from their salts by treatment with strong bases such as sodium or potassium hydroxide, sodium or potassium carbonate.
• the invention further relates to the use of the compounds of the formula I and their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route.
• they can be used together with at least one carrier or auxiliary and, if appropriate, in combination with one or more other active ingredient (s) are brought into a suitable dosage form.
• the invention further relates to agents, in particular pharmaceutical preparations, containing at least one compound of the formula I and / or one of its physiologically acceptable salts.
• agents in particular pharmaceutical preparations, containing at least one compound of the formula I and / or one of its physiologically acceptable salts.
• These preparations can be used as pharmaceuticals in human or veterinary medicine.
• Suitable carrier substances are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose or starch , Magnesium stearate, talc, petroleum jelly.
• Tablets, coated tablets, capsules, syrups, juices, drops or suppositories are used in particular for enteral administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for parenteral administration, and ointments, creams or powder for topical application.
• the new compounds can also be lyophilized and the lyophilizates obtained e.g. can be used for the production of injectables.
• the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colors, flavors and / or flavorings. If desired, they can also contain one or more other active ingredients, e.g. one or more vitamins.
• auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colors, flavors and / or flavorings.
• auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colors, flavors and / or flavorings.
• they can also contain one or more other active ingredients, e.g. one or more vitamins.
• the invention further relates to the use of the compounds of the formula I and their physiologically acceptable salts in the therapeutic treatment of human or animal body and in the control of diseases, in particular of schizophrenia and psychoreactive disorders and psychopathies, of depression, of severe chronic pain and of diseases which are associated with increased blood pressure.
• the compounds can also be used in the treatment of extrapyramidal disorders.
• the substances according to the invention are generally administered in analogy to known, commercially available preparations (thioridazine, haloperidol), preferably in doses between about 0.2 and 500 mg, in particular between 0.2 and 50 mg per dosage unit.
• the daily dosage is preferably between about 0.003 and 10 mg / kg body weight.
• the specific dose for each particular patient depends on a variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination, combination of drugs and The severity of the disease to which the therapy applies. Oral application is preferred.
• customary work-up means: if necessary, water is added, extracted with dichloromethane, separated, the organic phase is dried over sodium sulfate, filtered, evaporated and purified by chromatography on silica gel and / or by crystallization. Temperatures are given in ° C.
• a suspension of 4-phenyl-1- (4-phenylpicolinoyl) -1,2,3,6-tetrahydropyridine (obtainable by reaction of 4-phenylpicolinic acid with 4-phenyl-1,2,3,6-tetrahydropyridine in the presence of carbonyldiimidazole in THF) in 200 ml of THF is added dropwise to a suspension of 3.8 g of LiAlH4 in 200 ml of THF with stirring. The mixture is stirred for a further 2 hours at 20 °, worked up as usual and "P", dihydrochloride, melting point 223 ° (dec.).
• Example 1 The other compounds mentioned in Example 1 are obtained analogously from the corresponding acid amides.
• a suspension of 3.56 g of 2- (4-phenyl-1,2,3,6-tetrahydropyridyl-methyl) -6-m-methoxyphenyl-pyridine in 50 ml of 1,2-dichloroethane is added dropwise to a boiling solution of 15 , 6 g of dimethyl sulfide-boron tribromide complex in 50 ml of 1,2-dichloroethane, boil for 30 minutes, work up as usual and obtain 2- (4-phenyl-1,2,3,6-tetrahydropyridyl-methyl) -6- m-hydroxyphenyl pyridine.
• a mixture of 1 kg of "P" dihydrochloride, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
• Example B coated tablets
• Example A Analogously to Example A, tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
• a solution of 1 kg of "P" dihydrochloride in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.
• tablets, dragees, capsules and ampoules which contain one or more of the other active compounds of the formula I and / or their physiologically acceptable acid addition salts.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyridine Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (3)

Family

ID=6296716

Family Applications (1)

Country Status (11)

Cited By (2)

Citations (2)

• 1986
  • 1986-03-19 DE DE19863609142 patent/DE3609142A1/de not_active Withdrawn
• 1987
  • 1987-03-09 AT AT87103367T patent/ATE56005T1/de not_active IP Right Cessation
  • 1987-03-09 EP EP87103367A patent/EP0237908B1/fr not_active Expired - Lifetime
  • 1987-03-09 DE DE8787103367T patent/DE3764500D1/de not_active Expired - Fee Related
  • 1987-03-09 ES ES87103367T patent/ES2016941B3/es not_active Expired - Lifetime
  • 1987-03-16 KR KR870002347A patent/KR870008871A/ko not_active Application Discontinuation
  • 1987-03-17 AU AU70172/87A patent/AU596831B2/en not_active Ceased
  • 1987-03-18 ZA ZA871994A patent/ZA871994B/xx unknown
  • 1987-03-18 US US07/027,600 patent/US4906642A/en not_active Expired - Fee Related
  • 1987-03-18 HU HU871179A patent/HU196994B/hu not_active IP Right Cessation
  • 1987-03-18 PT PT84507A patent/PT84507B/pt not_active IP Right Cessation
  • 1987-03-19 JP JP62062814A patent/JPS62226977A/ja active Pending

Patent Citations (2)

Also Published As

Similar Documents

Legal Events